



Marine Drugs as a Valuable Source of Natural Biomarkers Used in the Treatment of Alzheimer's Disease

UMA NATH U^{1*} and DR LAL PRASANTH²

¹Department of pharmaceutical chemistry DM Wims college of pharmacy Wayanad

²Department of pharmaceutical Analysis, MGM College of pharmacy, pilathara, Kannur

*Corresponding author: Uma Nath U, Department of pharmaceutical chemistry DM Wims college of pharmacy Wayanad

ABSTRACT

Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder. Current approved drugs may only ameliorate symptoms in a restricted number of patients and for a restricted period of time. Currently, there is a translational research challenge into identifying the new effective drugs and their respective new therapeutic targets in AD and other neurodegenerative disorders. In this review, selected examples of marine-derived compounds in neuro degeneration, specifically in AD field are reported. The emphasis has been done on compounds and their possible relevant biological activities. The proposed drug development paradigm and current hypotheses should be accurately investigated in the future of AD therapy directions.

KEYWORDS: Marine drugs; Alzheimer's disease; Mechanisms of activity

INTRODUCTION

Right now, 46.8 million persons in the world are suffering from dementia and it is expected that this number will increase to 74.7 million in 2030 and 131.5 million in 2050. Alzheimer's disease (AD) is the main cause of dementia in the elderly. AD is a progressive, continuous and incurable brain disorder leading to increase severe disability such as memory loss (amnesia), minimal to no communication (aphasia), the inability to perform activities of daily living (ADL) (apraxia), the impairment of the sensory input (development of agnosias). In briefly, AD is a multifactorial neurodegenerative disorder that affects cognition (memory, thinking, and language abilities), quality of life and self-sufficiency in elderly [2]. AD is strictly related to aging, indeed the majority of cases ($\geq 90\%$) are initially diagnosed among persons ≥ 65 years of age (AD with late onset-LOAD). In particular, genes involved in the production of the amyloid β ($A\beta$) peptides such as amyloid precursor protein (APP), Presenilin 1 (PSEN1), and 2 (PSEN2) may account for as much as 5%–10% of the EOAD incidence.

BRYOSTATIN

Bryostatin 1 is a natural product derived from the

marine invertebrate *Bugula neritina*. It has potent and broad antitumor activity. Bryostatin 1 activates protein kinase C family members, with nanomolar potency for PKC1 α and ϵ isoforms.

In the central nervous system, bryostatin 1 activation of PKC boosts synthesis and secretion of the neurotrophic factor BDNF, a synaptic growth factor linked to learning and memory. The compound also activates nonamyloidogenic, α -secretase processing of amyloid precursor protein.

Preclinical work on bryostatin in nervous system diseases has mainly come from the Alkon lab. In their studies, intraperitoneal administration activated brain PKC ϵ and prevented synaptic loss, $A\beta$ accumulation, and memory decline in Alzheimer's disease transgenic mice. The drug preserved synapses and improved memory in aged rats, and in rodent models of stroke and Fragile X syndrome. In a different lab, bryostatin given by mouth improved memory and learning in an AD model. In a mouse model of multiple sclerosis, bryostatin promoted anti-inflammatory immune responses and improved neurologic deficits.




Figure1:




Figure2:

MACROALGAE

Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are important enzymes involved in the regulation of acetylcholine (ACh) in the cleft of neurons to promote cognitive function. However, loss or rapid degradation of acetylcholine leads to cholinergic dysfunction and synaptic ultimately memory impairment. Hence, cholinesterases

have been developed to alleviate cholinergic deficit by restoring ACh levels and improving cognitive function. Seaweed-derived biologically active compounds have been reported to exhibit inhibitory effects on enzymes associated with Alzheimer's disease. It was revealed that aqueous-ethanol extracts rich in phlorotannins, phenolic acids, and flavonoids from *Ecklonia maxima*, *Gelidium pristoides*, *Gracilaria*




Figure3:

gracilis, and *Ulva lactuca* exhibit acetylcholinesterase and butyrylcholinesterase inhibitory activities. Furthermore, sulfated polysaccharides obtained from *Ulva rigida* as well as the aforementioned algal species also showed potent inhibitory effects on BChE and AChE in vitro. Purified fractions of *Gelidiella acerosa* showed AChE and BChE inhibitory activity. Phytol was identified in the fraction as the most effective constituent. In the same study, molecular docking analysis revealed that phytol tightly binds to the arginine residue at the active site of the enzyme, thereby changing its conformation and exerting its inhibitory effect. AChE inhibitory activity of *Codium duthieae*, *Amphiroa beauvoisii*, *Gelidium foliaceum*, *Laurencia complanata*, and *Rhodomelopsis africana*. *Hypnea musciformis* and *Ochtodes secundiramea* extracts showed weak inhibitory activity (less than 30% inhibition) on AChE. Jung et al. also reported AChE and BChE inhibitory effects of methanol extracts of *Ecklonia cava*, *Ecklonia kurome*, and *Myelophycus simplex*. Glycoprotein isolated from *Undaria pinnatifida* showed dose responsive inhibitory effects on butyrylcholinesterase and acetylcholinesterase activities.

MEDITERRANEAN RED SEAWEED HALOPHYS INCURVA

The close relationship between the amyloid aggregation process and the onset of amyloidosis constantly encourages

scientific research in the identification of new natural compounds capable of suppressing the formation of toxic amyloid aggregates. For the first time, our findings demonstrated the in vitro anti-amyloidogenic role of the *H. incurva*, whose metabolic composition and bioactivity were strongly influenced by seasonality. This work focused on the bioactivity of *H. incurva* phytocomplex to evaluate the synergistic action of its various constituents, while the structure and functionality of its secondary metabolites will be the subject of further studies.

FASCAPLYSIN

Fascaplysin, a bis-indole alkaloid, was isolated from a marine sponge *Fascaplysinopsis Bergquist* sp. Fascaplysin is a specific kinase inhibitor for CDK 4.

References:

1. Rengasamy KR, Kulkarni MG, Stirk WA, Van Staden J (2014) Advances in algal drug research with emphasis on enzyme inhibitors. *Biotechnol Adv* 32: 1364-1381.
2. Hong DD, Hien HT (2008) Nutritional analysis of Vietnamese seaweeds for food and medicine No Title. *Biofactors* 22: 323-325.
3. Chengkui Z, Tseng C, Junfu Z, Chang CF (1984) Chinese seaweeds in herbal medicine. *Hdrobiologia* 116: 152-154.
4. Niazi AK, Kalra S, Irfan A, Islam A (2011) Thyroidology over the ages. *Indian J Endocrinol Metab* 15: S121-S126.

5. Yang Y (2009) Chinese Herbal Medicines: Comparisons and Characteristicstle; Churchill Livingstone: London, UK Volume 268.
6. Hamed SM, El Rhman AAA, Ibraheem IBM (2018) Role of marine macroalgae in plant protection & improvement for sustainable agriculture technology. Beni-Suef Univ J Basic Appl Sci 7: 104-110.
7. Wells MI, Potin P, Craigie JS, Raven JA, Merchant SS, et al. (2017) Algae as nutritional and functional food sources: Revisiting our understanding. J Appl Phycol 29: 949-982.
8. Kelman D, Posner EK, Mc Dermid KJ, Tabandera NK, Wright PR, Wright AD (2012) Antioxidant activity of Hawaiian marine algae. Mar Drugs 10: 403-416.
9. Moussavou G, Kwak DH, Obiang Obonou BF, Maranguy CA, Dinzouna Boutamba S, et al. (2014) Anticancer effects of different seaweeds on human colon and breast cancers. Mar Drugs 12: 4898-4911.
10. Riahi CR, Tarhouni S, Kharrat R (2011) Screening of anti-inflammatory and analgesic activities in marines macroalgae from Mediterranean Sea. Arch Inst Pasteur Tunis 88: 19-28.
11. Zhao C, Yang CF, Liu B, Lin L, Sarker SD, et al. (2018) Bioactive compounds from marine macroalgae and their hypoglycemic benefits. Trends Foods Sci Technol 72: 1-12.
12. Tierney MS, Croft AK, Hayes M (2010) A review of antihypertensive and antioxidant activities in macroalgae. Bot Mar 53: 387-408.
13. Pérez MJ, Falque E, Domingue H (2016) Antimicrobial action of compounds from marine seaweed. Mar Drugs 14: 52.
14. Pangestuti R, Kim SK (2011) Neuroprotective effects of marine algae. Mar Drugs 9: 803-818.
15. Alghazwi M, Kan YQ, Zhang W, Gai WP, Garson MJ, et al. (2016) Neuroprotective activities of natural products from marine macroalgae during 1999-2015. J Appl Phycol 28: 3599-3616.
16. Paris D, Beaulieu Abdelahad D, Bachmeier C, Reed J, Ait Ghezala G, et al. (2011) Anatabine lowers Alzheimer's A β production in *vitro* and in *vivo*. Eur J Pharmacol 670: 384-391.
17. Isik AT (2010) Late onset Alzheimer's disease in older people. Clin Interv Aging 5: 307-311.
18. Bekris LM, Yu C, Bird TD, Tsuang TW (2010) Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol 23: 213-227.
19. Yamazaki Y, Painter MM, Bu G, Kanekiyo T (2016) Apolipoprotein E as a therapeutic target in Alzheimer's disease: A review of basic research and clinical evidence. CNS Drugs 30: 773-789.
20. Liu C, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms, and Therapy. Nat Rev Neurol 9: 106-118.
21. Kim J, Basak JM, Holtzman DM (2009) The role of apolipoprotein E in Alzheimer's disease. Neuron 63: 287-303.
22. Shi Y, Yamada K, Liddelov SA, Smith ST, Zhao L, et al. (2017) ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549: 523-527.
23. Zhao Y, Zhao B (2013) Oxidative stress and the pathogenesis of Alzheimer's disease. Oxid Med Cell Longev: 316523.
24. Haam J, Yakel JL (2017) Cholinergic modulation of the hippocampal region and memory function. J Neurochem 142: 111-121.
25. Sadigh Eteghad S, Sabermarouf B, Majidi A, Talebi M, Farhoudi M, et al. (2015) Amyloid-beta: A crucial factor in Alzheimer's disease. Med Princ Pract 24: 1-10.
26. Reas XE (2017) Amyloid and tau pathology in normal cognitive aging. J Neurosci 37: 7561-7563.
27. Kametani F, Hasegawa M (2018) Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer's disease. Front Neurosci 12: 25.
28. Shal B, Ding W, Ali H, Kim YS, Khan S, et al. (2018) Anti-neuroinflammatory potential of natural products in attenuation of Alzheimer's disease. Front Pharmacol 9: 548.
29. Olasehinde TA, Olaniran AO, Okoh A (2017) Therapeutic potentials of microalgae in the treatment of Alzheimer's disease. Molecules 22: 480.
30. Obboh G, Nwanna EE, Oyeleye SI, Olasehinde TA, Ogunsuyi OB, et al. (2016) *In vitro* neuroprotective potentials of aqueous and methanol extracts from Heinsia crinita leaves. Food Sci. Hum. Wellness 5: 95-102.
31. Qui C, Kivipelto M, Strauss E (2009) Epidemiology of Alzheimer's disease: Occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 11: 111-128.
32. Graham WV, Bonito Oliva A, Sakmar TP (2017) Update on Alzheimer's disease therapy and prevention strategies. Annu Rev Med 68: 413-430.
33. Yiannopoulou KG, Papageorgiou SG (2013) Current and future treatments for Alzheimer's disease. Ther Adv Neurol Disord 6: 19-33.
34. Frozza RL, Lourenco MV, de Felice FG (2018) Challenges for Alzheimer's disease therapy: Insights from novel mechanisms beyond memory defects. Front Neurosci 12: 37.
35. Obboh G, Olasehinde TA, Ademosun AO (2014) Essential oil from lemon peels inhibit key enzymes linked to neurodegenerative conditions and pro-oxidant induced lipid peroxidation. J Oleo Sci 63: 373-381.
36. Olasehinde TA, Odjadjare EC, Mabinya LV, Olaniran AO, Okoh AI, et al. (2019) Chlorella sorokiniana and Chlorella minutissima exhibit antioxidant potentials, inhibit cholinesterases and modulate disaggregation of β -amyloid fibrils. Electron J Biotechnol 40: 1-9.
37. Obboh G, Adewuni TM, Ademosun AO, Olasehinde TA (2016) Sorghum stem extract modulates Na⁺/K⁺-ATPase, ecto-5'-nucleotidase, and acetylcholinesterase activities. Comp. Clin Pathol 25: 749-756.
38. Obboh G, Oyeleye SI, Akintemi OA, Olasehinde TA (2018) Moringa oleifera supplemented diet modulates nootropic-related biomolecules in the brain of STZ-induced diabetic rats treated with acarbose. Metab. Brain Dis 33: 457-466.
39. Obboh G, Adewuni TM, Ademiluyi AO, Olasehinde TA, Ademosun AO, et al. (2018) Phenolic constituents and inhibitory effects of Hibiscus sabdariffa L (Sorrel) calyx on cholinergic, monoaminergic, and purinergic enzyme activities. J Diet Suppl 15: 910-922.
40. Obboh G, Ademosun AO, Ogunsuyi OB, Oyedola ET, Olasehinde TA, et al. (2018) *In vitro* anticholinesterase, antimonoamine oxidase and antioxidant properties of alkaloid extracts from kola nuts (Cola acuminata and Cola nitida). J Complement Integr Med.
41. Olasehinde TA, Olaniran AO, Okoh AI (2019) Aqueous-ethanol extracts of some South African seaweeds inhibit beta-amyloid aggregation, cholinesterases, and beta-secretase activities in *vitro*. J Food Biochem 43: e12870.
42. Olasehinde TA, Mabinya LV, Olaniran AO, Okoh AI (2019) Chemical characterization of sulfated polysaccharides from Gracilaria gracilis and Ulva lactuca and their radical scavenging, metal chelating, and cholinesterase inhibitory activities. Int J Food Prop 22: 100-110.
43. Olasehinde TA, Mabinya LV, Olaniran AO, Okoh AI (2019)

- Chemical characterization, antioxidant properties, cholinesterase inhibitory and anti-amyloidogenic activities of sulfated polysaccharides from some seaweeds. *Bioact. Carbohydr. Diet Fibre* 18: 100182.
44. Syad AN, Rajamohamed BS, Shunmugaiah KP, Devi PK (2016) Neuroprotective effect of the marine macroalga *Gelidium acerosa*: Identification of active compounds through bioactivity-guided fractionation. *Pharm. Biol* 54: 2073-2081.
 45. Rengasamy KR, Amoo SO, Aremu AO, Stirk WA, Gruz J, et al. (2015) Phenolic profiles, antioxidant capacity, and acetylcholinesterase inhibitory activity of eight South African seaweeds. *J Appl Phycol* 27: 1599-1605.
 46. Jung SH, Young UM, Inho K, Suengmok C, Daeseok H, et al. (2016) In *vitro* screening for anti-dementia activities of seaweed extracts. *J Korean Soc Food Sci Nutr* 45, 966-997.
 47. Rafiquzzaman SM, Ki EY, Lee JM, Mohibullah M, Badrul Alam M (2015) Anti-Alzheimers and anti-inflammatory activities of a glycoprotein purified from the edible brown alga *Undaria pinnatifida*. *Food Res Int* 77: 118-124.
 48. Shanmuganathan B, Sheeja MD, Sathya S, Devi PK (2015) Antiaggregation potential of *Padina gymnospora* against the toxic Alzheimer's beta-amyloid peptide 25-35 and cholinesterase inhibitory property of its bioactive compounds. *PLoS ONE* 10: e0141708.
 49. Castro Silva ES, Bello M, Hernández Rodríguez M, Correa Basurto J, Murillo Álvarez JI (2018) Rosales-Hernández, M.C.; Muñoz-Ochoa, M. In vitro and insilico evaluation of fucosterol from *Sargassum horridum* as potential human acetylcholinesterase inhibitor. *J Biomol Struct Dyn*.
 50. Choi BW, Lee HS, Shin H, Lee BH (2015) Multifunctional activity of polyphenolic compounds associated with a potential for Alzheimer's disease therapy from *Ecklonia Cava*. *Phytother Res* 29: 549-553.
 51. Sathya M, Premkumar P, Karthick C, Moorthi P, Jayachandran KS, et al. (2012) BACE1 in Alzheimer's disease. *Clin Chim Acta* 24: 171-178.
 52. Cheng X, He P, Lee T, Yao H, Li R, et al. (2014) High activities of BACE1 in brains with mild cognitive impairment. *Am J Pathol* 184: 141-147.
 53. Rockenstein E, Mante M, Alford M, Adame A, Crews L, et al. (2005) High β -secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid- β levels. *J Biol Chem* 280: 32957-32967.
 54. Jung HA, Ali MY, Choi RJ, Jeong HO, Chung HY, et al. (2016) Kinetics and molecular docking studies of fucosterol and fucoxanthin, BACE1 inhibitors from brown algae *Undaria pinnatifida* and *Ecklonia stolonifera*. *Food Chem Toxicol* 89: 104-111.
 55. Seong SH, Ali MY, Kim HR, Jung HA, Choi JS (2017) BACE1 inhibitory activity and molecular docking analysis of meroterpenoids from *Sargassum serratifolium*. *Bioorg Med Chem* 25: 3964-3970.
 56. Wagle A, Seong SH, Zhao BT, Woo MH, Jung HA, et al. (2018) Comparative study of selective in vitro and in silico BACE1 inhibitory potential of glycyrrhizin together with its metabolites, 18a- and 18b-glycyrrhetic acid, isolated from *Hizikia fusiformis*. *Arch Pharm Res* 41: 409-418.
 57. Dong X, Wang Y, Qin Z (2009) Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. *Acta Pharm Sin* 30: 379-387.
 58. Fernandes F, Barbosa M, Oliveira AP, Azevedo IC, Sousa Pinto I, et al. (2016) The pigments of kelps (Ochrophyta) as part of the flexible response to highly variable marine environments. *J Appl Phycol* 28: 3689-3696.
 59. Kim JJ, Kang YJ, Shin SA, Bak DH, Lee JW, et al. (2016) Phlorofucofuroeckol improves glutamate-induced neurotoxicity through modulation of oxidative stress-mediated mitochondrial dysfunction in PC12 cells. *PLoS ONE* 11: 0163433.
 60. O'Brien RJ, Wong BC (2011) Amyloid precursor protein processing and Alzheimer's disease. *Annu. Rev. Neurosci* 34: 185-204.
 61. Giffin JC, Richards RC, Craft C, Jahan N, Leggiadro C, et al. (2017) An extract of the marine alga *Alaria esculenta* modulates α -synuclein folding and amyloid formation. *Neurosci Lett* 22: 87-93.
 62. Syad AN, Devi KP (2015) Assessment of anti-amyloidogenic activity of marine red alga *G. acerosa* against Alzheimer's beta-amyloid peptide 25-35. *Neurol Res* 37: 14-22.
 63. Alghazwi M, Smid S, Zhang W (2018) In *vitro* protective activity of South Australian marine sponge and macroalgae extracts against amyloid beta (A β 1-42) induced neurotoxicity in PC-12 cells. *Neurotoxicol Teratol* 68: 72-83.
 64. Gan SY, Wong LZ, Wong JW, Tan EL (2019) Fucosterol exerts protection against amyloid β -induced neurotoxicity, reduces intracellular levels of amyloid β and enhances the mRNA expression of neuroglobin in amyloid β -induced SH-SY5Y cells. *Int J Biol Macromol* 121: 207-213.
 65. Alghazwi M, Smid S, Karpinić S, Zhang W (2019) Comparative study on neuroprotective activities of fucoidans from *Fucus vesiculosus* and *Undaria pinnatifida*. *Int J Biol Macromol* 122: 255-264.
 66. Yang EJ, Ahn S, Ryu J, Choi M, Choi S, et al. (2015) Phloroglucinol attenuates the cognitive deficits of the 5XFAD mouse model of Alzheimer's disease. *PLoS ONE* 10: e0135686.
 67. Wang J, Zheng J, Huang C, Zhao J, Lin J, et al. (2018) Eckmaxol, a phlorotannin extracted from *Ecklonia maxima*, produces anti- β -amyloid oligomer neuroprotective effects possibly via directly acting on glycogen synthase kinase 3 β . *ACS Chem Neurosci* 9: 1349-1356.
 68. Oh JH, Choi JS, Nam T (2018) Fucosterol from an edible brown alga *Ecklonia stolonifera* prevents soluble amyloid beta-induced cognitive dysfunction in aging rats. *Mar Drugs* 16: 368.
 69. Lin J, Yu J, Zhao J, Zhang K, Zheng J, et al. (2017) Fucoxanthin, a marine carotenoid, attenuates β -amyloid oligomer-induced neurotoxicity possibly via regulating the PI3K/Akt and the ERK pathways in SH-SY5Y cells. *Oxid Med Cell Longev* 2: 6792543.
 70. Zhao X, Zhang S, A C, Zhang H, Sun Y, Li Y, Pu X (2015) Neuroprotective effect of fucoxanthin on β -amyloid induced cell death. *J Chin Pharm Sci* 24: 467-470.
 71. Wei H, Gao Z, Zheng L, Zhang, Liu Z, et al. (2017) Protective effects of fucoidan on A β 25-35 and d-Gal-induced neurotoxicity in PC12 cells and d-Gal-induced cognitive dysfunction in mice. *Mar Drugs* 15: 77.
 72. Sathya R, Kanaga N, Sankar P, Jeeva S (2017) Antioxidant properties of phlorotannins from brown seaweed *Cystoseira trinodis* (Forsskål) C. Agardh. *Arab J Chem* 10: S2608-S2614.